MSB 2.38% $1.23 mesoblast limited

Ann: Update on Scheduled FDA Advisory Committee Meeting, page-177

  1. 268 Posts.
    lightbulb Created with Sketch. 41
    Everyone seems to be ignoring the political consequences of NOT approving AGVHD at this point.

    Without approval for AGVHD it's not a simple label extension for Covid-19 / ARDS in three weeks time. The political optics of recommending for Covid-19 / ARDS (admittedly from a very clear cut quad blinded phase3 trial) but requiring yet another trial for the sick children, is horrible.

    Remember that the FDA can approve regardless of the AdCom result... The bodies are stacking up in the meantime.

    [ Not that I think the AdCom result will be negative ]


    Last edited by jb13qz: 12/08/20
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.23
Change
-0.030(2.38%)
Mkt cap ! $1.404B
Open High Low Value Volume
$1.26 $1.30 $1.22 $10.22M 8.142M

Buyers (Bids)

No. Vol. Price($)
2 11752 $1.23
 

Sellers (Offers)

Price($) Vol. No.
$1.23 67205 1
View Market Depth
Last trade - 16.10pm 29/05/2024 (20 minute delay) ?
Last
$1.23
  Change
-0.030 ( 3.67 %)
Open High Low Volume
$1.26 $1.29 $1.22 1670014
Last updated 15.59pm 29/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.